Schaff, Lauren R. http://orcid.org/0000-0002-4664-670X
Lobbous, Mina
Carlow, Dean
Schofield, Ryan
Gavrilovic, Igor T.
Miller, Alexandra M.
Stone, Jacqueline B.
Piotrowski, Anna F.
Sener, Ugur
Skakodub, Anna
Acosta, Edward P.
Ryan, Kevin J.
Mellinghoff, Ingo K.
DeAngelis, Lisa M.
Nabors, Louis B.
Grommes, Christian
Article History
Received: 26 July 2021
Accepted: 17 December 2021
First Online: 13 January 2022
Declarations
:
: The study was approved by the institutional review board at each participating institution and performed in accordance with the Declaration of Helsinki. All accrued patients provided written informed consent. This trial was registered at ExternalRef removed as NCT03684980 26/09/2018.
: Not applicable.
: LRS: Research support: BTG; Consultant: DebioPharm; pending patent related to the content of the manuscript. ML, DC, RS, ITG, AMM, JS, AFP, US, AS, EPA, KJR: No disclosures. IKM: Honoraria: Roche; Research Support: Amgen, General Electric, Lilly, Kazia Therapeutics; Consultant: Agios, Black Diamond Therapeutics, DebioPharm, Puma Biotechnology, Voyager Therapeutics, DC Europa Ltd., Kazia Therapeutics, Novartis, Cardinal Health, Roche, Vigeo Therapeutics, Samus Therapeutics.LMD: Scientific Advisory Board: Sapience Therapeutics; pending patent related to the content of the manuscript. LBN: Scientific Advisory Board: BTG, plc, Karyopharm; pending patent related to the content of the manuscript. CG: Research Support: Pharmacyclics, Bayer, BMS; Consultant: Kite, BTG, ONO; pending patent related to the content of the manuscript.